CClinicalTrials.gg
Enrolling by invitationNCT06278103MethylRH-MUpdated Feb 26, 2024

Correlation Between Expression of Hormonal Receptors, Clinical Data, and Methylation Profile in Meningiomas (MethylRH-M)

An observational study in Meningioma, sponsored by Central Hospital, Nancy, France. Enrolling by invitation. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-26.

Sponsored by Central Hospital, Nancy, France · Observational

From the registry’s dates

  • Primary completion was expected by Jul 2024, 2 years 3 months ago, but the record still lists the study as enrolling by invitation.
Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
180
Ages
18 Years and older
Sex
All
01

Study summary

This research aims to explore the relationship between hormonal receptor expression and the clinical and histopathological characteristics of meningiomas. The underlying hypothesis is that hormonal receptor expression, as well as the methylation profile of their gene promoters, are associated with specific aspects of meningiomas and patients' clinical outcomes. The main objective is to study the correlation between the immunohistochemical expression of hormonal receptors and clinicopathological data. The secondary objectif is to study the correlation between the methylation profile of hormonal receptor gene promoters and their immunohistochemical expression.

02

Conditions studied

  • Meningioma

Browse trials for

Keywords

  • Meningioma
  • Hormonal receptors
03

In context

Meningioma

226 studies on the registry are indexed under Meningioma; 87 are open to participants now.

This study's planned enrollment of 180 is above the median of 132 across 56 observational studies indexed under Meningioma.

Browse Meningioma studies →

Lead sponsor

Central Hospital, Nancy, France is the lead sponsor of 778 studies on the registry; 183 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients who underwent surgery for a meningioma at the University Hospital of Nancy between 2000 and 2022.

Inclusion criteria

  • Patients who underwent surgery for a meningioma at the University Hospital of Nancy between 2000 and 2022.

Exclusion criteria

Exclusion Criteria:

  • Patients who did not express their consent to participate in the study.
  • Patients with grade 2 or 3 meningiomas whose samples are no longer available or in insufficient quantity to perform an immunohistochemical study.
  • Patients with grade 1 meningiomas not selected by randomization.
  • Patients withdrawing their consent.
05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
180 participants (estimated)
Target follow-up
24 Years
Patient registry
Yes
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. immunohistochemical expression of different hormonal receptors

    Evaluated on FFPE sections

    Time frame: up to 24 years after surgery

Secondary outcomes

  1. methylation profile of the promoters of hormonal receptor genes

    Methylation profile established from frozen tissue.

    Time frame: up to 24 years after surgery

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06278103
Lead sponsor
Central Hospital, Nancy, France
Responsible party
Guillaume GAUCHOTTE (Professor, Central Hospital, Nancy, France) — Principal investigator
First posted
Feb 26, 2024
Start date
Jan 1, 2000
Primary completion
Jul 1, 2024 (estimated)
Completion
Sep 1, 2024 (estimated)
Last update
Feb 26, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion